Antilipidemic adherence post-coronary artery disease diagnosis among those with and without an ICD-9 diagnosis of depression

Journal of Psychosomatic Research

Volumn 69, Issue 2, 2010, Pages 169-174

  May, Heidi T ^a   Sheng, Xiaoming ^b   Catinella, A Peter ^b   Horne, Benjamin D ^a,b   Carlquist, John F ^a,b   Joy, Elizabeth ^b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Adherence; Antidepressant medication; Coronary artery disease; Depression

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC PATIENT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DEPRESSION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; PREDICTION; PRESCRIPTION; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; STATISTICS AS TOPIC;

EID: 77954625343     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2010.01.026     Document Type: Article

References (29)

1. Murray C, Lopez A Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
2. Barth J, Schumacher M, Herrman-Lingen C Depression as a risk factor for mortality in patients with coronary heart disease. Psychosom Med 2004, 66:802-822.
3. van Melle JP, de Jonge P, Spikerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004, 66:814-822.
4. Rugulies R Depression as a predictor for the development of coronary heart disease: a systematic review and meta-analysis of the literature. Am J Prev Med 2003, 23:51-61.
5. DiMatteo MR, Lepper HS, Croghan TW Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000, 160:2101-2107.
6. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004, 45:394-402.
7. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002, 17:504-511.
8. Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB The relationship of depressive symptoms to symptom reporting, self-care, and glucose control in diabetes. Gen Hosp Psychiatry 2003, 25:246-252.
9. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED Long-term adherence with cardiovascular drug regimens. Am Heart J 2006, 151:185-191.
10. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000, 160:1818-1823.
11. Rieckmann N, Gerin W, Kronish IM, Burg MM, Chaplin WF, Kong G, et al. Course of depressive symptoms and medication adherence after acute coronary syndromes. J Am Coll Cardiol 2006, 48:2218-2222.
12. Lappé JM, Muhlestein JB, Lappé DL, Badger RS, Bair TL, Brockman R, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004, 141:446-453.
13. Irvine J, Baker B, Smith J, Jandciu S, Paguette M, Cairns J, et al. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med 1999, 61:566-575.
14. Bogner HR, de Vries HF Integratin of depression and hypertension treatment: A pilot, randomized controlled trial. Ann Fam Med 2008, 6:295-301.
15. Grundy SM, Cleeman JI, Merz NB, Brewer HB, Clark LT, Hunninghake DB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Circulation 2004, 110:227-239.
16. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
17. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002, 360:1623-1630.
18. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
19. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
20. Gehi A, Haas D, Pipkin S, Whooley MA Depression and medication adherence in outpatients with coronary heart disease. Arch Intern Med 2005, 165:2508-2513.
21. Anonymous Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med 1984, 310:750-758.
22. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998, 136:792-803.
23. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12.
24. Everson SA, Kaplan GA, Goldberg DE, Salonen R, Salonen JT Hoplessness and 4-year progression of carotid atherosclerosis. The Kuopio Ischemic Heart Disease Risk Factor Study. Arterioscler Thromb Vasc Biol 1997, 17:1490-1495.
25. Song X, Huse DM, Williams SA, Borok GM, McDonough K, Ozminkowski RJ A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs. J Occup Environ Med 2006, 48:1014-1022.
26. Franco OH, Peeters A, Looman CW, Bonneux L Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 2005, 59:927-933.
27. Horne R, Weinman J Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999, 47:555-567.
28. Blazer GD, Hughes DC, George LK The epidemiology of depression in an elderly community population. Gerontologist 1987, 27:281-287.
29. Fancher T, Kravitz R In the clinic: depression. Ann Intern Med 2007, 146:ITC5.1-ITC5.16.